Prof. Raymond S. Douglas was employed as Visiting Professor of ZOC and Lectured entitled “Novel Medical Therapy of Thyroid Eye Disease”
Source: Zhongshan Ophthalmic Center of Sun Yat-sen University
Edited by: Liu Nian
On the morning of December 1st, 2017, a simple and elaborated ceremony was held in Zhongshan Ophthalmic Center (ZOC). The Director of the Orbital and Thyroid Eye Disease Center at Cedars-Sinai Medical Center in California, Prof. Raymond S. Douglas was employed as visiting professor of ZOC. The engage ceremony was hosted by the director of department of Orbital Disease and Eye Tumor, Prof. Huasheng Yang.
At the beginning of the ceremony, the director of ZOC, Prof. Yizhi Liu read off the personal academic achievement of prof. Raymond S. Douglas. On behalf of ZOC, Prof. Yizhi Liu expressed a warm welcome to Prof. Raymond S. Douglas and presented the letter of “visiting professor”. Under the leadership of Prof. Huasheng Yang on foreland research fields of Thyroid-associated Disease, we made a further communication with Prof. Raymond S. Douglas in this field and expected an collaborative agreement in the research. Then Prof. Raymond S. Douglas visited the State Key Laboratory of Ophthalmology, China.
Expert Profile:
Professor Raymond S. Douglas is the Director of the Orbital and Thyroid Eye Disease Center at Cedars-Sinai Medical Center in California. Previously, he was the director of Thyroid Eye Disease Center at University of Michigan Kellogg Eye Center, and principal investigator of the nation’s largest multi-center clinical trial project of thyroid eye disease. Under the leadership of Professor Douglas, the Kellogg Eye Center has been a global leader in the field of treatment and research of Thyroid Eye Disease. He is devoted to the basic and clinical research of Thyroid Eye Disease, and has published 106 papers in SCI journals such as Nat Rev Endocrinol, PNAS, Blood, Ophthalmology and IOVS. He recently published positive results in the New England Journal of Medicine regarding a new drug for the treatment of thyroid eye disease. The study drug (Teprotumumab), designated as a breakthrough therapy by the Food and Drug Administration, represented a key milestone in providing the first safe and effective treatment for Graves’ eye disease.
